On March 5, 2024 RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, reported the acceptance of three late-breaking abstracts for poster presentation, including a poster presentation for tivumecirnon (FLX475), its lead oncology drug candidate, highlighting phase 2 clinical data in head and neck squamous cell carcinoma (HNSCC), at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting which will take place April 5-10, 2024 in San Diego, CA (Press release, RAPT Therapeutics, MAR 5, 2024, https://investors.rapt.com/news-releases/news-release-details/rapt-therapeutics-announces-multiple-late-breaking-presentations [SID1234640790]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Late-breaking poster presentation details:

Title:
Phase 2 Study of Oral CCR4 Antagonist FLX475 (tivumecirnon) Plus Pembrolizumab in Subjects with Head and Neck Squamous Cell Carcinoma (HNSCC) Previously Treated with Checkpoint Inhibitor
Abstract Number:
CT226
Date & Time:
Tuesday, April 9, 2024; 9:00 a.m. – 12:30 p.m. PT
Session Title:
Phase II Clinical Trials 1
Location:
Poster Section 49

Title:
A Combined mregDC and Treg Signature Associates with Antitumor Efficacy of CCR4 Antagonist Tivumecirnon FLX475
Abstract Number:
2485
Date & Time:
Monday, April 8, 2024; 9:00 a.m. – 12:30 p.m. PT
Session Title:
Predictive Biomarkers 1
Location:
Poster Section 43

Title:
HPK1 inhibits CD8+ T cell effector gene expression following T cell activation
Abstract Number:
2654
Date & Time:
Monday, April 8, 2024; 1:30 – 5:00 p.m. PT
Session Title:
Immune Checkpoints and Inhibitory Molecules 2
Location:
Poster Section 4

Late-breaking abstract titles are currently available on AACR (Free AACR Whitepaper)’s online itinerary planner, and late-breaking abstract text will be available on AACR (Free AACR Whitepaper)’s planner on April 5, 2024 at 12:00 p.m. PT. The planner can be accessed at: View Source!/20272.